Investigation of the SSRI augmentation properties of 5-HT2 receptor antagonists using in vivo microdialysis

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Frank P. Bymaster, David O. Calligaro, Julie F. Falcone et al. · Neuropsychopharmacology · 1996 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist

G.A. Kennett, Martyn Wood, Fiona Bright et al. · Neuropharmacology · 1997 · 524 citations · Full text

Medicine, Neuroscience, Pharmacology +12

A Novel Augmentation Strategy for Treating Resistant Major Depression

Richard C. Shelton, Gary D. Tollefson, Mauricio Tohen et al. · American Journal of Psychiatry · 2001 · 515 citations

Pharmacy, Pharmacotherapy, Psychiatry +12

Interaction between a selective 5‐HT_1Areceptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT

Sarah E. Gartside, Valerie Umbers, Mihály Hajós et al. · British Journal of Pharmacology · 1995 · 313 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

Mark J. Millan, Anne Dekeyne, Alain P. Gobert · Neuropharmacology · 1998 · 283 citations

Life Sciences, Neuroscience, Pharmacology +12